Benign Prostatic Hyperplasia (BPH) References

Disease Prevention and Treatment, 5th edition

The references on this page correspond with the print version of Disease Prevention and Treatment, 5th edition. Since we continuously update the protocols online in response to new scientific developments, readers are encouraged to review the latest versions of the protocols.

  1. Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Experimental Gerontology. 2005;40:121-128.
  2. Harvard Health Publications. Special Health Reports. 2012 Annual Report of Prostate Diseases. Available at: http://www.harvardhealthcontent.com/SpecialHealthReports/70,PA0212?Page=Section9. Accessed October 29, 2012.
  3. Mayo Clinic. Prostate gland enlargement. Definition. Available at: http://www.mayoclinic.com/health/prostate-gland-enlargement/DS00027. Last updated December 6, 2011. Accessed October 29, 2012.
  4. Merck Manual. Benign prostatic hyperplasia (BPH). Available at: http://www.merckmanuals.com/home/mens_health_issues/prostate_disorders/benign_prostatic_hyperplasia_bph.html. Last updated October 2008. Accessed October 29, 2012.
  5. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC). Prostate enlargement: benign prostatic hyperplasia. Available at: http://kidney.niddk.nih.gov/kudiseases/pubs/prostateenlargement/. Last update March 23, 2012. Accessed October 29, 2012.
  6. Sarma AV and Wei JT. Benign prostatic hyperplasia and lower urinary tract symptoms. The New England Journal of Medicine. 2012;367(3):248-257.
  7. Ho CK, Nanda J, Chapman KE, Habib FK. Oestrogen and benign prostatic hyperplasia: effects on stromal cell proliferation and local formation from androgen. The Journal of endocrinology. Jun 2008;197(3):483-491.
  8. Matsuda T, Abe H, Suda K. [Relation between benign prostatic hyperplasia and obesity and estrogen]. Rinsho byori. The Japanese journal of clinical pathology. Apr 2004;52(4):291-294.
  9. Vermeulen A, Kaufman JM, Goemaere S, van Pottelberg I. Estradiol in elderly men. The aging male : the official journal of the International Society for the Study of the Aging Male. Jun 2002;5(2):98-102.
  10. Sciarra F, Toscano V. Role of estrogens in human benign prostatic hyperplasia. Archives of andrology. May-Jun 2000;44(3):213-220.
  11. Jasuja GK, Travison TG, Davda M, Murabito JM, Basaria S, Zhang A, . . . Bhasin S. Age Trends in Estradiol and Estrone Levels Measured Using Liquid Chromatography Tandem Mass Spectrometry in Community-Dwelling Men of the Framingham Heart Study. The journals of gerontology. Series A, Biological sciences and medical sciences. Oct 25 2012.
  12. Barnard RJ, Aronson WJ. Benign prostatic hyperplasia: does lifestyle play a role? The Physician and sportsmedicine. Dec 2009;37(4):141-146.
  13. Kozak I, Bartsch W, Krieg M, Voigt KD. Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. The Prostate. 1982;3(5):433-438.
  14. Burnett-Bowie SA, Roupenian KC, Dere ME, Lee H, Leder BZ. Effects of aromatase inhibition in hypogonadal older men: a randomized, double-blind, placebo-controlled trial. Clinical endocrinology. Jun 25 2008.
  15. McNicholas T and Mitchell S. Benign prostatic hyperplasia. Surgery. 2008;26(5):218-222.
  16. Lepor, H. Pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. Reviews in Urology. 2004;6(9):S3-S10.
  17. Prins GS, Korach KS. The role of estrogens and estrogen receptors in normal prostate growth and disease. Steroids. Mar 2008;73(3):233-244.
  18. Suzuki K, Okazaki H, Ono Y, Kurokawa K, Suzuki T, Onuma E, . . . Yamanaka H. Effect of dual inhibition of 5-alpha-reductase and aromatase on spontaneously developed canine prostatic hypertrophy. The Prostate. Oct 1 1998;37(2):70-76.
  19. Sarma AV and Wei JT. Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms. NEJM. 2012;367:248-57.
  20. Zhang W, Wang X, Liu Y, et al. Effects of dietary flaxseed lignan extract on symptoms of benign prostatic hyperplasia. Journal of Medicinal Food. 2008;11(2):207-214.
  21. Lakhey M, Ghimire R, Shrestha R, Bhatta AD. Correlation of serum free prostate-specific antigen level with histological findings in patients with prostatic disease. Kathmandu University Medical Journal. 2010;8(2):158-163.
  22. USPSTF (United States Preventive Services Taskforce). Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Published 5/2012. Accessed 10/31/2012 at http://www.uspreventiveservicestaskforce.org/prostatecancerscreening/prostatefinalrs.htm#summary.
  23. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, . . . Auvinen A. Screening and prostate-cancer mortality in a randomized European study. The New England journal of medicine. Mar 26 2009;360(13):1320-1328.
  24. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, . . . Lilja H. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. The lancet oncology. Aug 2010;11(8):725-732.
  25. Kjellman A, Akre O, Norming U, Tornblom M, Gustafsson O. 15-year followup of a population based prostate cancer screening study. The Journal of urology. Apr 2009;181(4):1615-1621; discussion 1621.
  26. Sandblom G, Varenhorst E, Rosell J, Lofman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow-up. Bmj. 2011;342:d1539.
  27. Nickel, JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia. The International Journal of Clinical Practice. 2008a;62(10):1547-1559.
  28. Elterman DS, Barkin J, Kaplan SA. Optimizing the management of benign prostatic hyperplasia. Therapeutic Advances in Urology. 2012;4(2):77-83.
  29. Azzouni F and Mohler J. Role of 5α-reductase inhibitors in benign prostatic diseases. Prostate Cancer and Prostatic Diseases. 2012;15:222-230.
  30. Traish AM, Hassani J, Guay AT, et al. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. Journal of Sexual Medicine. 2011;8:872-881
  31. Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, . . . Too CK. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. The Journal of urology. Jan 2008;179(1):147-151.
  32. Fenter TC, Davis EA, Shah MB, Lin PJ. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or =65 years. The American journal of managed care. May 2008;14(5 Suppl 2):S154-159.
  33. Choi YH, Cho SY, Cho IR. The different reduction rate of prostate-specific antigen in dutasteride and finasteride. Korean journal of urology. Oct 2010;51(10):704-708.
  34. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU international. Aug 2011;108(3):388-394.
  35. Festuccia C, Gravina GL, Muzi P, Pomante R, Angelucci A, Vicentini C, Bologna M. Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. The Journal of urology. Jul 2008;180(1):367-372.
  36. Makridakis N, Reichardt JK. Pharmacogenetic analysis of human steroid 5 alpha reductase type II: comparison of finasteride and dutasteride. Journal of molecular endocrinology. Jun 2005;34(3):617-623.
  37. Borawski KM and Culley CC. Detrusor-directed therapy in men with benign prostatic hyperplasia. Cur Bladder Dysfunc Rep. 2011;6:218-223.
  38. Roumeguere T, Boudjeltia KZ, Hauzeur C, et al. Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? British Journal of Urology International. 2009;103:511-517.
  39. Laydner HK, Oliveira P, Oliveira CRA, et al. Phosphodiesterase 5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review. British Journal of urology International. 2010;107:1104-1109.
  40. Gacci M, Corona G, Salvi M, et al. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with a-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. European Urology. 2012;61:994-1003.
  41. McVary KT, Roherborn CG, Avins AL, et al. Update on aua guideline on the management of benign prostatic hyperplasia. The Journal of Urology. 2011;185:1193-1903.
  42. Roehrborn CG. Sexual function and benign prostatic hyperplasia. Reviews in Urology. 1999: 157-157.
  43. Gravenstein D. Transurethral resection of the prostate (turp) syndrome: a review of the pathophysiology and management. Anesthesia and Analgesia. 1997;84:438-446.
  44. Reich O, Gratzke C, Bachmann A, et al. Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients. The Journal of Urology. 2008;180:146-249.
  45. Schroeck FR, Hollingsworth JM, Kaufman SR, Hollenbeck BK, Wei JT. Introduction of laset technology and procedure use for benign prostatic hyperplasia: data from Florida. Urology. 2012;80:678-683.
  46. Mangera A, Chapple CR. Use of botulinum toxin in the treatment of lower urinary tract disorders. Current status. Archivos espanoles de urologia. Dec 2010;63(10):829-841.
  47. Hamidi Madani A, Enshaei A, Heidarzadeh A, Mokhtari G, Farzan A, Mohiti Asli M, Esmaeili S. Transurethral intraprostatic Botulinum toxin-A injection: a novel treatment for BPH refractory to current medical therapy in poor surgical candidates. World journal of urology. Mar 13 2012.
  48. Yokoyama T, Yamamoto Y, Suzuki T, Oguma K, Nagai A. Intraprostatic botulinum neurotoxin type a injection for benign prostatic hyperplasia: preliminary results with a newly purified neurotoxin. Acta medica Okayama. 2012;66(4):291-297.
  49. Arnouk R, Suzuki Bellucci CH, Stull RB, de Bessa Junior J, Malave CA, Gomes CM. Botulinum neurotoxin type a for the treatment of benign prostatic hyperplasia: randomized study comparing two doses. TheScientificWorldJournal. 2012;2012:463574.
  50. Kristal AR, Arnold KB, Schenk JM, et al. Dietary patterns, supplement use and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology. 2008;167(8):925-934.
  51. Rohrmann S, Giocannucci E, Willett WC, Platz EA. Fruit and vegetable consumption, intake of micronutirents and benign prostatic hyperplasia in US men. The American Journal of Clinical Nutrition. 2007;85(2):523-529.
  52. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. Urology. 2007;178:395-401.
  53. Wilt TJ, Ishani A, Stark G, et al. Saw palmetto extracts for treatment of benign prostatic hyperplasia. Journal of the American Medical Association. 1998;280(18):1604-1614.
  54. Gordan AE, Shaughnessy AF. Saw palmetto for prostate disorders. Am Fam Physician. 2003;67(6):1281-3.
  55. Suter A, Saller R, Riedi E, Heinrich M. Improving BPH symptoms and sexual dysfunctions with a saw palmetto preparation? Results from a pilot trial. Phytotherapy Research. 2013; 27(2):218-26. Epub 2012 Apr 23.
  56. Habib FK. Serenoa repens: the scientific basis for the treatment of benign prostatic hyperplasia. European Urology Supplements. 2009;8:887-893.
  57. Sokeland J. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome. BJU International. 2000;86:439-442.
  58. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. The Cochrane Library, 2012;5.
  59. Avins AL, Bent S, Staccone S, et al. A detailed safety assessment of a saw palmetto extract. Complementary Therapies in Medicine. 2008;16:147-154.
  60. Dedhia RC and McVary KT. Phytotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology., 2008;179:2119-2125.
  61. Sorenson WR, Sullivan D. Determination of campesterol, stigmasterol, and beta-sitosterol in saw palmetto raw materials and dietary supplements by gas chromatography: collaborative study. Journal of AOAC International. May-Jun 2007;90(3):670-678.
  62. Jones PJ, AbuMweis SS. Phytosterols as functional food ingredients: linkages to cardiovascular disease and cancer. Current opinion in clinical nutrition and metabolic care. Mar 2009;12(2):147-151.
  63. Choudhary SP, Tran LS. Phytosterols: perspectives in human nutrition and clinical therapy. Current medicinal chemistry. 2011;18(29):4557-4567.
  64. Rocha M, Banuls C, Bellod L, Jover A, Victor VM, Hernandez-Mijares A. A review on the role of phytosterols: new insights into cardiovascular risk. Current pharmaceutical design. Dec 1 2011;17(36):4061-4075.
  65. Genser B, Silbernagel G, De Backer G, Bruckert E, Carmena R, Chapman MJ, . . . Marz W. Plant sterols and cardiovascular disease: a systematic review and meta-analysis. European heart journal. Feb 2012;33(4):444-451.
  66. Othman RA, Moghadasian MH. Beyond cholesterol-lowering effects of plant sterols: clinical and experimental evidence of anti-inflammatory properties. Nutrition reviews. Jul 2011;69(7):371-382.
  67. Coleman CI, Hebert JH, Reddy P. The effect of phytosterols on quality of life in the treatment of benign prostatic hyperplasia. Pharmacotherapy. Nov 2002;22(11):1426-1432.
  68. Wilt TJ, MacDonald R, Ishani A. beta-sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU international. Jun 1999;83(9):976-983.
  69. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane database of systematic reviews. 2000(2):CD001043.
  70. Shi H, Cheng L, Zheng X, Tu L. [Study of effects and mechanism of phytosterols on chronic abacterial prostatitis]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. Nov 2010;35(22):3033-3037.
  71. Shenouda NS, Sakla MS, Newton LG, Besch-Williford C, Greenberg NM, MacDonald RS, Lubahn DB. Phytosterol Pygeum africanum regulates prostate cancer in vitro and in vivo. Endocrine. Feb 2007;31(1):72-81.
  72. Kobayashi Y, Sugaya Y, Tokue A. [Clinical effects of beta-sitosterol (phytosterol) on benign prostatic hyperplasia: preliminary study]. Hinyokika kiyo. Acta urologica Japonica. Dec 1998;44(12):865-868.
  73. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. German BPH-Phyto Study group. British journal of urology. Sep 1997;80(3):427-432.
  74. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group. Lancet. Jun 17 1995;345(8964):1529-1532.
  75. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU international. May 2000;85(7):842-846.
  76. Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA. Randomized trial of a combination of natural products (cernitin, saw palmetto, B-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). International urology and nephrology. 2001;33(2):217-225.
  77. Lowe FC and Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: an update. Urology. 1999;53:671-678.
  78. Quiles MT, Arbos MA, Fraga A, et al. Antiproliferative and apoptotic effects of the herbal agent pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH). The Prostate. 2010;70:1044-1053.
  79. Wilt TJ and Ishani A. Pygeum africanum for benign prostatic hyperplasia. The Cochrane Library. 2011;9.
  80. Murakami M, Tsukada O, Okihara K, et al. Beneficial effect of honeybee-collected pollen lump extract on benign prostatic hyperplasia (BPH). Food Science and Technology Research. 2008;14(3):306-310.
  81. Xu J, Qian WQ, Song JD. A comparative study on different doses of cernilton for preventing the clinical progression of benign prostatic hyperplasia. Zhonghua Nan Ke Zue. 2008;14(6):533-537.
  82. Alt. Med. Rev. Urtica dioica; Urtica urens (Nettle). Monograph. Alternative medicine review. Sep 2007;12(3):280-4.
  83. Nahara A and Dixit VK. Ameliorative effects of stinging nettle (urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia. 2012;44 Suppl 1:396-409.
  84. Safarinejad MR. Urtica dioica for Treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study. Journal of Herbal Pharmacotherapy. 2005;5(4):1-11.
  85. Kumar NB, Cantor A, Allen K, et al. The specific role of isoflavones in reducing prostate cancer risk. Prostate. 2004;59:141-147.
  86. Evans BA, Griffiths K, Morton MS. Inhibition of 5a-redutase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. Journal of Endocrinology. 1995;147:295-302.
  87. Hong SJ, Kim SI, Kwon SM, et al. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonaci Medical Journal. 2002;43(2):236-241.
  88. Brossner C, Petritsch K, Fink K, et al. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology. 2004;64:707-711.
  89. Jared RA, Keikha M, Dowling C, et al. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiology, Biomarkers and Prevention. 2002;11(12):1689-1696.
  90. Wong CW, Wong EL, Li H, et al. Isoflavones in treating watchful waiting benign prostate hyperplasia: a double-blinded, randomized controlled trial. The Journal of Alternative and Complementary Medicine. 2012;18(1):54-60.
  91. Tsai YS, Tong YC, Cheng JT, et al. Pumpkin seed oil and phytosterol-f can block testosterone/prazosin-induced prostate growth in rats. Urologia Internationalis. 2006;77:269-274.
  92. Gossell-Williams M, Davis A, O’Connor N. Inhibition of testosterone-induced hyperplasia of the prostate of sprague-dawly rats by pumpkin seed oil. Journal of Medicinal Food. 2006;9(2):284-286.
  93. Abdel-Rahman ME. Effect of pumpkin seed (Cucurbita pop L.) diets on benign prostatic hyperplasia (BPH): chemical and morphometric evaluation in rats. World Journal of Chemistry. 2006;1(1):33-40.
  94. Hong H, Kim CS, Maeng S. Effects of pumpkin seed oil and saw palmetto oil in korean men with symptomatic benign prostatic hyperplasia. Nutrition Research and Practice. 2009;3(4):323-327.
  95. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Research. 1999;59:1225-1230.
  96. Obermuller-Jevic UC, Olano-Martin E, Corbacho AM, et al. Lycopene inhibits the growth of normal human prostate epithelial cells in vitro. biochemical and molecular actions of nutrients. Journal of Nutrition. 2003;133:3356-3360.
  97. Kucuk O, Sarkar FH, Sakr W, et al. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology, Biomarkers and Prevention, 2001;10:861-868.
  98. Simopoulos AP. Essential fatty acids in health and chronic disease. Am J Clin Nutr. 1999;70(3):560-569.
  99. Shaikh SR. Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. The Journal of nutritional biochemistry. Feb 2012;23(2):101-105.
  100. James MJ, Gibson RA, Cleland LG. Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr. 2000;71(1):343-348.
  101. Demark-Wahnefried W, Robertson CN, Walther PJ, et al. Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate specific antigen. Urology. 2004;63(5):900-904.
  102. Pham H and Ziboh VA. 5a-Reductase-catalyzed conversion of testosterone to dihydrotestosterone is increased in prostatic adenocarcinoma cells: suppression by 15-lipoxygenase metabolites of gamma-linolenic and eicosapentaenoic acids. Steroid Biochemistry and Molecular Biology, 2002;82:393-400.
  103. Alt. Med. Rev. Boswellia serrata. Monograph. Alternative medicine review : a journal of clinical therapeutic. Jun 2008;13(2):165-167.
  104. Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clinical pharmacokinetics. Jun 2011;50(6):349-369.
  105. Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, . . . Bitto A. Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia. British journal of pharmacology. Sep 2012;167(1):95-108.
  106. Nickel JC. Inflammation and Benign Prostatic Hyperplasia. Urol Clin North Am. 2008b February; 35(1): 109–115
  107. Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, . . . Liu M. Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis. Cancer research. Jul 15 2009;69(14):5893-5900.
  108. Yuan HQ, Kong F, Wang XL, Young CY, Hu XY, Lou HX. Inhibitory effect of acetyl-11-keto-beta-boswellic acid on androgen receptor by interference of Sp1 binding activity in prostate cancer cells. Biochemical pharmacology. Jun 1 2008;75(11):2112-2121.
  109. Lu M, Xia L, Hua H, Jing Y. Acetyl-keto-beta-boswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells. Cancer research. Feb 15 2008;68(4):1180-1186.
  110. Thomas JA. Diet, micronutritents and the prostate gland. Nutrition Reviews. 1999;57(4):95-103.
  111. Altavilla D, Bitto A, Polito F, et al. the combination of serenoa repens, selenium and lycopene is more effective than serenoa repens alone to prevent hormone dependent prostatic growth. The Journal of Urology. 2011;186:1524-1529.
  112. Eichholzer M, Steinbrecher A, Kaaks R, et al. Effects of selenium status, dietary glucosinolate intake and serum glutathione s-transferase a activity on the risk of benign prostatic hyperplasia. BJU International. 2012;Epub.
  113. Devrim E and Dursk I. Is garlic a promising food for benign prostatic hyperplasia and prostate cancer. Molecular Nutrition and Food Research. 2007;51:1319-1323.
  114. Tavani A, Longoni E, Bosetti C, et al. Intake of selected micronutrients and the risk of surgical treated benign prostatic hyperplasia: a case-control study from Italy. European Urology. 2006;50:549-554.